Page 6 - Graphite Bio News Today

Lodestar Private Asset Management LLC purchased a new stake in shares of Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 14,199 shares of the company’s stock, valued at approximately $47,000. A number of other hedge funds and other institutional investors have also bought and sold […]

Prime-edited hematopoietic stem cells from sickle cell disease patients can engraft and help treat genetic blood disorders in mice.

Graphite Bio (NASDAQ:GRPH – Get Rating) and Compugen (NASDAQ:CGEN – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Volatility and Risk Graphite Bio has a beta of 0.01, […]

Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) and Graphite Bio (NASDAQ:GRPH – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation. Volatility & Risk Sangamo Therapeutics has a beta of […]

Forget about He Jiankui, the Chinese scientist who created gene-edited babies. Instead, when you think about gene editing you should think of Victoria Gray, the African-American woman who says she’s been cured of her sickle-cell disease symptoms.  This week in London, scientists are gathering for the Third International Summit on Human Genome Editing. It’s gene…

Compugen (NASDAQ:CGEN – Get Rating) and Graphite Bio (NASDAQ:GRPH – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations. Profitability This table compares Compugen and Graphite Bio’s net margins, […]

In this article, we will take a look at the 11 most promising gene editing stocks according to analysts.

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Research analysts at SVB Leerink upped their Q1 2023 EPS estimates for shares of Graphite Bio in a research report issued on Monday, March 20th. SVB Leerink analyst M. Foroohar now expects that the company will post earnings per share of ($0.13) for the quarter, up from […]

Jonathan MacQuitty talks about cell and gene therapy shortcomings and the challenges for private companies at different funding stages in 2023.

BioPharma